Compare MARA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MARA | APGE |
|---|---|---|
| Founded | 2010 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | MARA | APGE |
|---|---|---|
| Price | $9.64 | $77.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | $22.23 | ★ $99.44 |
| AVG Volume (30 Days) | ★ 39.2M | 931.0K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 242.35 | N/A |
| EPS | ★ 2.12 | N/A |
| Revenue | ★ $919,173,000.00 | N/A |
| Revenue This Year | $49.39 | N/A |
| Revenue Next Year | $13.71 | N/A |
| P/E Ratio | $4.51 | ★ N/A |
| Revenue Growth | ★ 53.52 | N/A |
| 52 Week Low | $9.43 | $26.20 |
| 52 Week High | $23.45 | $80.99 |
| Indicator | MARA | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 29.73 | 65.21 |
| Support Level | $9.61 | $73.55 |
| Resistance Level | $10.69 | $80.44 |
| Average True Range (ATR) | 0.66 | 3.12 |
| MACD | 0.03 | -0.53 |
| Stochastic Oscillator | 5.38 | 66.80 |
MARA Holdings Inc leverages digital asset compute to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value. The company also offers technology solutions to optimize data center operations, including next-generation liquid immersion cooling and firmware for bitcoin miners. It is focused on computing for, acquiring, and holding digital assets as a long-term investment.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.